Fri.May 31, 2024

article thumbnail

ASCO: In surprise, J&J's injectable Rybrevant extends lung cancer patients' lives versus intravenous version

Fierce Pharma

When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. | When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. But to Johnson & Johnson’s surprise, a subcutaneous formulation of its lung cancer med Rybrevant proved to work better than the original infusion.

Patients 274
article thumbnail

FDA Approves Moderna RSV Vaccine, an mRNA Alternative to GSK and Pfizer Products

MedCity News

Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won their FDA nods last year. The post FDA Approves Moderna RSV Vaccine, an mRNA Alternative to GSK and Pfizer Products appeared first on MedCity News.

FDA 108
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Summit, Akeso's antibody triumphs over Keytruda in China lung cancer trial, sending shares skyrocketing

Fierce Pharma

Just one week after Summit Therapeutics and Akeso’s bispecific antibody ivonescimab passed muster with Chinese regulators, the drug has pulled off another feat by staring down the PD-1 king Keytrud | In the phase 3 HARMONi-2 trial, solo ivonescimab delivered a statistically significant and clinically meaningful improvement in progression-free survival over Keytruda monotherapy.

251
251
article thumbnail

Novartis cues up filings for remibrutinib in chronic hives

pharmaphorum

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data from two phase 3 trials.

111
111
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Moderna, with FDA nod for RSV vaccine, grows reach beyond the pandemic

Fierce Pharma

With the FDA nod, Moderna's RSV vaccine becomes the company's second product to secure the FDA's backing.

FDA 299
article thumbnail

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

pharmaphorum

The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it down earlier this year.

FDA 111

More Trending

article thumbnail

MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Courtney Fortner, CEO of Navvis

MedCity News

In this month’s episode, Senior Reporter Katie Adams explored some executive moves and layoffs that recently occurred in the healthcare world. She also interviewed Courtney Fortner, who stepped into the CEO role at population health company Navvis this month. The post MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Courtney Fortner, CEO of Navvis appeared first on MedCity News.

article thumbnail

Fierce Pharma Asia—Takeda plots US layoffs; AZ, Daiichi suffer trial setback; Asahi Kasei strikes buyout deal

Fierce Pharma

Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to show an overall survival benefit in a lung cancer study. | Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to prove an overall survival benefit in a lung cancer study. Japan's Asahi Kasei is moving to buy rare disease drugmaker Calliditas for about $1 billion.

Pharma 140
article thumbnail

FDA grants RMAT status for BlueRock’s Parkinson’s therapy

Pharmaceutical Technology

The US FDA has granted RMAT designation for BlueRock Therapeutics' cell therapy, bemdaneprocel (BRT-DA01), for Parkinson's disease.

FDA 105
article thumbnail

Good news in Europe, bad news in US for Sanofi and Regeneron's COPD bid for Dupixent

Fierce Pharma

A highly anticipated decision on Sanofi and Regeneron’s Dupixent to become the first biologic to treat chronic obstructive pulmonary disorder (COPD) is on hold in the United States but is speeding | A highly anticipated decision on Sanofi and Regeneron’s Dupixent to become the first biologic to treat chronic obstructive pulmonary disorder (COPD) is on hold in the United States but is speeding along in Europe.

Medicine 130
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Oligonucleotide ALS therapy approved in EU

European Pharmaceutical Review

The first treatment approved in the EU to target a genetic cause of amyotrophic lateral sclerosis (ALS), has been authorised by the European Commission (EC). QALSODY ® (tofersen) is indicated for adults with ALS associated with a mutation in the superoxide dismutase 1 gene ( SOD1 -ALS). The treatment is an antisense oligonucleotide (ASO) designed to bind to SOD1 mRNA to reduce SOD1 protein production, Biogen shared.

article thumbnail

Dupixent nears EU approval for COPD, as FDA delays

pharmaphorum

Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive pulmonary disease (COPD). The CHMP’s positive opinion sets up Dupixent (dupilumab) to become the first biologic therapy for COPD in the EU and the first new treatment approach for the disease in over a decade.

FDA 105
article thumbnail

Experiencing BCBA Burnout? Why It Happens and Tips to Combat It

MedCity News

What contributes to the stress and what BCBA employers can do to alleviate it The post Experiencing BCBA Burnout? Why It Happens and Tips to Combat It appeared first on MedCity News.

93
article thumbnail

9 Preventive Healthcare Marketing Strategies

Healthcare Success

Marketing the importance of preventive healthcare services is challenging, costly, and often conflicts with consumer behavior. Despite these hurdles, the urgency to promote prevention has never been greater. Why? The growing number of people diagnosed with preventable chronic diseases each year is staggering (think cancer cases resulting from smoking and diabetes and heart disease cases resulting from obesity).

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Talkspace, Labcorp’s Ovia Health Launch Digital Women’s Health Coalition

MedCity News

Talkspace and Ovia Health by Labcorp introduced the Women’s Health Coalition for Digital Solutions. Other founding member companies of the coalition include Conceive, Evernow, FitOn, Nurx, Cove and Nutrium. The post Talkspace, Labcorp’s Ovia Health Launch Digital Women’s Health Coalition appeared first on MedCity News.

88
article thumbnail

NHS platform announced to accelerate personalised cancer vaccine clinical trials

PharmaTimes

The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines

99
article thumbnail

Work Friction: The Sleeper Crisis Plaguing Healthcare Contact Centers

MedCity News

How work friction takes shape, how it costs organizations, and how leaders can uncover long-term solutions The post Work Friction: The Sleeper Crisis Plaguing Healthcare Contact Centers appeared first on MedCity News.

article thumbnail

Gilead’s Trodelvy woes rise with failed bladder cancer trial

pharmaphorum

Gilead's TROP2 ADC Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma.

110
110
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer

MedCity News

Gilead Sciences reported Trodelvy’s Phase 3 test in metastatic urothelial cancer fell short of showing a statistically significant benefit on the overall survival main goal. The antibody drug conjugate had received accelerated FDA approval for this type of cancer in 2021. The post Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer appeared first on MedCity News.

FDA 74
article thumbnail

The Crick announces new partnerships with SMEs and MRC for research

PharmaTimes

The projects will focus on a range of research areas, including Down’s syndrome and ALS

article thumbnail

Healthcare Moves: A Monthly Summary of Hires and Layoffs

MedCity News

Here is a selection of recent executive hires, promotions, retirements and layoffs occurring across the healthcare industry. The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.

article thumbnail

Pharma Pulse 5/31/24: Gen Z’s Passion for Skincare Falls Short on Sun Protection, A Long, But Promising Road Ahead in Clinical Trials & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 104
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Regeneron Global Program Head of Linvoseltamab Discusses the Potential for Linvoseltamab to Become a Frontline Treatment for Multiple Myeloma

PharmExec

In an interview with Pharm Exec Associate Editor Don Tracy, Karen Rodriguez-Lorenc, Global Program Head of Linvoseltamab, Regeneron talks about the possibility of linvoseltamab becoming a frontline treatment for multiple myeloma (MM) as well as the company's VelociSuite technology.

52
article thumbnail

Tips to Increase New Patient Revenue

Penrod

1. Personalize Collection Strategies Looking at your historical data can help you create a compelling collection plan for specific patients. Another invaluable tool is the data from a financial clearing house. It’ll help you identify the likelihood of a patient paying and those that might not. You can use this information to determine the best course of action, including decisions to send a patient’s account to a professional collection agency.

article thumbnail

Scemblix Shows Improved Major Molecular Response Treating Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

PharmExec

Results of a Phase III trial indicated that Scemblix was more effective than standard-of-care tyrosine kinase inhibitors in treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

52
article thumbnail

Closing the Gap: How Rep-Lite Bridges the Talent Gap in Med Device Sales

Rep-Lite

The medical device industry is booming with innovations, but a significant challenge persists with the talent gap. As demand for skilled medical sales representatives in medical device sales continues to rise, companies often struggle to find the right talent to drive their business forward. However, not anymore. At Rep-Lite , an experienced medical sales recruitment agency , we find and hire the most competent healthcare sales representatives for medical device sales.

Sales 52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Regeneron Global Program Head of Linvosoltamab Discusses the Potential for Linvosoltamab to Become a Frontline Treatment for Multiple Myeloma

PharmExec

In an interview with Pharm Exec Associate Editor Don Tracy, Karen Rodriguez-Lorenc, Global Program Head of Linvosoltamab, Regeneron talks about the possibility of linvoseltamab becoming a frontline treatment for multiple myeloma (MM) as well as the company's Velocsuite technology.

52
article thumbnail

European Commission approves Biogen’s QALSODY for ALS treatment

Pharmaceutical Technology

The EC has approved Biogen's QALSODY to treat adults with amyotrophic lateral sclerosis (ALS) linked to SOD1-ALS mutation.

59
article thumbnail

Virtual Therapeutics, Akili Interactive Strike Definitive Merger Agreement Seeking to Improve Mental Health Through Immersive Video Games

PharmExec

Under terms of the deal, Akili will become a wholly owned subsidiary of Virtual Therapeutics, with Akili shareholders receiving $0.4340 per share of common stock in cash.

52
article thumbnail

Midland Pharmaceuticals launches to advance spinal injury therapeutics

Pharmaceutical Technology

Midland Pharmaceuticals has launched to focus on the development of a therapeutic for spinal cord injury and cerebrovascular disease.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A